Advanced glycation in D-galactose induced mouse aging model.

Area of Science:

• Biogerontology
• Biochemistry
• Immunology

Background:

• D-galactose injection in mice models accelerated aging, exhibiting neurological, antioxidant, and immune deficits.
• The underlying mechanism of D-galactose-induced aging remains unclear.
• D-galactose is a reducing sugar that can form advanced glycation endproducts (AGEs) in vivo.

Purpose of the Study:

• To investigate the role of advanced glycation endproducts (AGEs) in D-galactose-induced accelerated aging.
• To determine if AGE formation is the primary mechanism behind the observed aging phenotypes.

Main Methods:

• 5-month-old C57 mice were injected daily for 8 weeks with D-galactose, AGE-lysine, L-glucose, L-lysine, or control buffer.
• Two groups received aminoguanidine, an AGE formation inhibitor, alongside D-galactose.
• Evaluated parameters included serum AGE levels, cognitive function, skin hydroxyproline, motor activity, lymphocyte proliferation, IL-2 production, and SOD activity.

Main Results:

• D-galactose, L-glucose, and AGE-lysine treatments significantly increased serum AGEs, impaired memory, and elevated skin hydroxyproline.
• These groups showed decreased motor activity, reduced lymphocyte response, lower IL-2 production, and diminished SOD activity, mirroring aged controls.
• Aminoguanidine treatment in D-galactose-injected mice prevented these aging-like changes.

Conclusions:

• D-galactose and L-glucose can form AGEs in vivo, contributing to accelerated aging.
• Elevated AGEs are a significant factor in the D-galactose-induced mouse aging model.
• Advanced glycation partially explains the mechanism of this accelerated aging model.